|
Published by: NeuroInsights, LLC
Published: May. 18, 2007 - 369 Pages
Table of Contents
- 01 Executive Summary
- The Brain Industry Revealed
- Investment Risks and Opportunities
- Neurotechnology and Society
- Key Industry Facts and Findings
- Timeline of Advances in Neuroscience
- 02 Trends and Drivers
- Converging Technologies
- Stem Cells and Neuroregeneration
- Neuroimaging and Disease Treatment
- Crossing the Blood Brain Barrier
- Demographic Drivers
- More People Living Longer
- Social Drivers
- The Life Style Improvement Market
- Economic Drivers
- Worldwide Economic Burden
- Rising Healthcare Costs
- Research Funding
- United States Government
- International Research Funding
- Foundations Focus on the Brain
- Regulatory Trends
- International Regulatory Competition
- Intellectual Property Trends
- Global Intellectual Property Protection
- Neuropharmaceutical Patent Expirations
- Patent Activity in the US: 1980-2004
- Selected Neurotechnology Patents
- 03 Neuropharmaceutical Sector
- Cogniceutical Market
- Alzheimer's Disease
- Mild Cognitive Impairment
- Attention Deficit Disorders
- Sleep Disorders
- Emoticeutical Market
- Depression
- Anxiety Disorders
- Sensoceutical Market
- Chronic Pain
- Retinal and Optic Nerve Disorders
- Epilepsy and Seizure Disorders
- Parkinson's Disease
- Other Markets
- Schizophrenia and Psychosis
- Addiction and Substance Abuse
- Obesity
- Stroke
- 04 Neurodevice Sector
- Neuroprosthetic Devices
- Cochlear Implants
- Retinal Implants
- Motor Prostheses & Brain-Computer Interface
- Neurostimulation Devices
- Brain Stimulation
- Spinal Cord Stimulation
- Vagus Nerve Stimulation
- Peripheral Nerve Stimulation
- Neurosurgical Devices
- Neurosurgical Navigation Equipment
- Radiosurgical Devices
- Neurovascular Intervention
- Neurosoftware
- Attention Deficit Disorders
- Pain Control
- Age-related Disorders
- 05 Neurodiagnostic Sector
- Neuroimaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI, fMRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Electroencephalography (EEG)
- Magnetoencephalography (MEG)
- In Vitro Diagnostics
- Genetic Testing and Pharmacogenomics
- Protein Biomarker Assays
- Neuroinformatics
- Patient Dataset Management
- Open Source Software
- 06 Private Neurotech Investment
- U.S. Venture Capital Investment 1999-2004
- Neurotech Venture Capital 1999-2004
- Largest Neurotech Investments 1999-2004
- Leading Neurotech Venture Capital Firms
- 07 Public Neurotech Investment
- Neurotech Initial Public Offerings 2004-Q12006
- Neurotech M&A activity
- Neuropharma Research and Licensing Deals
- NeuroInsights' Neurotech Index
- Neurotech Index Performance
- 08 Leading Research Centers
- University of California, San Francisco (UCSF)
- Massachusetts Institute of Technology (MIT)
- University of California, San Diego (UCSD)
- Harvard University
- Stanford University
- University of California, Los Angeles (UCLA)
- Columbia University
- University College London (UCL)
- Karolinska Institutet, Stockholm
- RIKEN Brain Science Institute, Japan
- Places to Watch
- 09 Leading Neurotechnology Regions
- The Global Neurotech Economy
- Nexus Ranking and Methodology
- Establish Neurotech Nexus'
- Emerging Neurotech Nexus'
- Nascent Neurotech Nexus'
- Conclusions and Policy Recommendations
- 10 Company Profiles
- Neuropharmaceutical Companies
- Private
- Public
- Neurodevice Companies
- Private
- Public
- Neurodiagnostic Companies
- Private
- Public
- The Neurotechnology Industry 2007 Report: Exhibits, Tables, and Charts:
- 1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications
- 1-2: Global Pharmaceutical Sales by Indication, 2005
- 1-3: Neurotechnology Industry Taxonomy
- 1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity
- 1-5: NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index
- 2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020
- 2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2011
- 2-3: Neurotechnology Patent Approvals, US, 1985-2005
- 2-4: Neuropharmaceutical Patent Approvals, US, 1985-2005
- 2-5: Neurodevice Patent Approvals, US, 1985-2005
- 2-6: Neurodiagnostic Patent Approvals, US, 1985-2005
- 2-7: Selected US Foundations with a Significant focus on Brain Research and Education
- 2-8: Most Generous Philanthropists for Medical and Brain Research
- 2-9: Global Stem Cell Policy Map
- 3-1: Pharmaceutical Sales in Top 13 World Markets by therapeutic class, 2001-2005
- 3-2: Neuropharmaceutical Markets, Worldwide Sales in 2005
- 3-3: Number of people Afflicted and Market Size by Type of Neuropsychiatric Disorder
- 3-4: Neuropharmaceutical Revenues by Indication in 2004
- 3-5: FDA Pharmaceutical Approval Process
- 3-6: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)
- 3-7: Clinical Trials for Mild Cognitive Impairment (same for all clinical trial tables)
- 3-8: Clinical Trials for ADHD
- 3-9: Clinical Trials for Sleep Disorders
- 3-10: Clinical Trials for Depression
- 3-11: US Sales of Leading SSRI and SNRIs, 1999-2005
- 3-12: Clinical Trials for Anxiety disorders
- 3-13: Clinical Trials for Pain
- 3-14: US Sales of Leading COX-2 Inhibitors, 1999-2005
- 3-15: Clinical Trials for Retinal and Optic Nerve Disorders
- 3-16: Clinical Trials for Epilepsy
- 3-17: Clinical Trials for Parkinson’s disease
- 3-18: Clinical Trials for Schizophrenia and Psychosis
- 3-19: US Sales of Leading Anti-psychotics, 1999-2005
- 3-20: Clinical Trials for Addition and Substance Abuse
- 3-21: Clinical Trials for Obesity Treatment
- 3-22: Clinical Trials for Stroke Treatment
- 4-1: New Neurodevice FDA Registrations, 1996-2005
- 4-2: FDA Classification and Approval Process for Medical Devices
- 4-3: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J
- 4-4: Neurodevice Markets (Neuroprosthetic, Neurostimulation, Neurosurgical, Neurofeedback)
- 4-5: Neurostimulation Device Clinical Trials
- 5-1: Neurodiagnostics Markets (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)
- 5-2: FDA Approval and Insurance Reimbursement of Diagnostics
- 5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)
- 5-4: Projected Number of Pharmacogenetic Tests by Indication 2003-2013
- 5-5: Medical Divisions of Fortune 500 Dominate Neuroimaging Market
- 5-6: Alzheimer’s Disease Neuroimaging Initiative
- 5-7: Neuroinformatics Data Storage
- 5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
- 6-1: Total US Venture Capital Investment, 1999-2005
- 6-2: US Life Science Venture Capital Investment, 1999-2005
- 6-3: US Neurotechnology Venture Capital Investment, 1999-2005
- 6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2005
- 6-5: Top Five Neurotechnology Venture Capital Financings, 2000-2005
- 6-6: Top 10 Neurotech Venture Capital Firms with Investments
- 7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2006
- 7-2: Selected Neurotech M&A Activity, 2004-Q1 2006
- 7-3: Selected Neuropharmaceutical Research and Licensing Deals 2004-Q1 2006
- 7-4: Neurotech Index Companies 2006
- 7-2: Neurotech Index Company Fundamentals
- 7-3: Index Company Performance
- 8-1 Leading Neurotechnology Research Centers
- 8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry
- 8-3: UCSF
- 8-4: UCLA
- 8-5: Harvard University
- 8-6: Stanford University
- 8-7: MIT
- 8-8: Columbia University
- 8-9: Washington University
- 8-10: University College London
- 8-11: Karolinska Institute
- 8-12: RIKEN Brain Science Institute
- 9-1 NeuroInsights’ 2005 Leading Neurotech Nexus Ratings
- 9-2 Conclusions and Policy Recommendations
- 10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
- 10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
- 10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
AbstractThe Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is a market analysis and strategic investment guide of the global neurological disease and psychiatric illness markets. The report focuses on the more than 500 public and private companies translating advances in neuroscience into tomorrow's treatments. It provides insight and analysis of issues such as corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry. The report provides an in-depth look at fifteen brain and central nervous system disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, memory decline, obesity, pain, Parkinson's, psychiatric disorders, stroke and other brain-related illnesses.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
